DefiniGEN

DefiniGEN

Private
CambridgeHealthcare & Life Scienceshttps://definigen.com

Last Round

Series B

Nov 19, 2020

Total Funding Raised

$14.58M

Momentum Score

25 /100

Company Overview

DefiniGEN is a biotechnology company that provides diseased cells models for drug discovery and research solutions. The company's products are stem cell life science products that generate high-functionality cell types, including liver, pancreatic, and lung cells, enabling medical clients to accelerate their research and optimize their workflow.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

iPSC-derived cellscontract research organizationCROdrug discoveryhuman cell modelsinduced pluripotent stem cellsiPSCpreclinical researchdisease modelsdisease-in-a-dishgene-editing servicesCRISPRdrug toxicity testingiPSC-derived hepatocytesorganoidsiPSC differentiationcontract research services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DefiniGEN Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

DefiniGEN Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BNov 19, 2020
GrantSep 24, 2019
GrantApr 1, 2019
GrantJan 1, 2019
Follow-on OfferingMay 23, 2016
Grant
Jan 1, 2016

DefiniGEN Investors

Notable investors and investment history

InvestorRounds
Innovate UKGrant
Ranworth CapitalSeries A
BGFSeries B
Cambridge Capital GroupSeries A, Follow-on Offering
Cambridge EnterpriseSeed, Series A, Follow-on Offering
London Business AngelsSeries A
Parkwalk AdvisorsSeed, Follow-on Offering

DefiniGEN Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

DefiniGEN Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about DefiniGEN's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge
Employee Range16
Year Founded2011
Last FundingNov 19, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.